SCHEMBL7657770

SCHEMBL7657770

Cc1cc2oc(-c3ccc(O)c(O)c3)c(O)c(=O)c2cc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 11/20 0.68
KMT2A Q03164 11/20 0.68
KDM4E B2RXH2 9/20 0.68
MAPT P10636 9/20 0.68
CYP3A4 P08684 8/20 0.68
HSD17B10 Q99714 8/20 0.68
TP53 P04637 7/20 0.68
RECQL P46063 6/20 0.68
CDK2 P24941 6/20 0.68
ALOX15 P16050 6/20 0.68
CYP2C9 P11712 6/20 0.68
MAPK1 P28482 5/20 0.68
ALDH1A1 P00352 5/20 0.68
HPGD P15428 5/20 0.68
LMNA P02545 4/20 0.68
CDK5 Q00535 3/20 0.68
CDK5R1 Q15078 3/20 0.68
ALOX12 P18054 3/20 0.68
AMY1A P0DUB6 3/20 0.68
APP P05067 3/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7656375 0.89 MEN1 (0.62) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL10037939 0.88 MEN1 (0.76) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL25209431 0.86 MAPT (0.57) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL14697045 0.85 TUBB4A (0.65) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL14697047 0.85 MAPT (0.74) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL7659883 0.84 MAPT (0.71) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL12378689 0.84 MEN1 (0.75) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL10067898 0.82 ADORA3 (0.71) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL20496405 0.81 CDK2 (0.59) MEN1KMT2AKDM4EMAPTCYP3A4
SCHEMBL14259664 0.81 TUBB4A (0.70) MEN1KMT2AKDM4EMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103929959-A Neuroprotective polyphenol analogs SALK INST FOR BIOLOGICAL STUDI 2014-07-16 CN claimed
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-07-03 US claimed
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2014-07-03 US claimed
EP-2741609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS Salk Institute for Biological Studies (US) 2014-06-18 EP claimed
WO-2013025484-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA LAPCHAK PAUL A (US) 2013-02-21 WO claimed
WO-2013025498-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SCHUBERT DAVID R (US) 2013-02-21 WO claimed
EP-1109800-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LIMITED (KR) 2001-06-27 EP claimed
WO-2000012496-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LTD. (KR) 2000-03-09 WO claimed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-9744164-B2 Neuroprotective polyphenol analogs SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2017-08-29 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2016-07-21 US disclosed
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2012-01-19 US disclosed
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2012-01-19 US disclosed
WO-2010105253-A2 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2010-09-16 WO disclosed
US-6500846-B1 2-(4-CHLOROPHENYL)-7-METHOXYCHROMEN-4-ONE, AS CYCLIN-DEPENDENT KINASE INHIBITORS, USED AS ANTICARCINOGENIC AGENTS OR FOR PROPHYLAXIS OF NEURODEGENERATIVE DISEASE LG CHEMICAL, LTD. (KR) 2002-12-31 US disclosed
EP-1109800-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LIMITED (KR) 2001-06-27 EP disclosed
WO-2000012496-A1 NOVEL CDK INHIBITORS HAVING FLAVONE STRUCTURE LG CHEMICAL LTD. (KR) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140186329-A1 POLYPHENOL ANALOGS TO TREAT ISCHEMIA GPX1, KEAP1, GPX4 MEN1 4434/4885KMT2A 1403/4885KDM4E 1055/4885
US-20140186328-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS GSR, IAPP, GCLC MEN1 2624/4885KMT2A 2552/4885KDM4E 3072/4885
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES SLC5A2, LIPG, TIE1 MEN1 2979/4885KMT2A 3540/4885KDM4E 1794/4885
US-20160206609-A1 NEUROPROTECTIVE POLYPHENOL ANALOGS GSR, IAPP, GCLC MEN1 2624/4885KMT2A 2552/4885KDM4E 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.